Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 11c

August 5, 2021 4:28 PM EDT

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.53), $0.11 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $8.95 million versus the consensus estimate of $7.85 million.

We are very pleased with our second quarter 2021 results. The commercialization of DANYELZA® (naxitamab-gqgk) is... More